Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Headquarters Switzerland

Address Lichtstrasse 35, Basel, 4056


Telephone 41 61 3241111

No of Employees 108,000

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange NOVN (SWF)

Revenue (2021) $52.9B 6% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 197.6% (2021 vs 2020)

Market Cap* $185.9B

Net Profit Margin (2021) XXX 180.8% (2021 vs 2020)

* As of and is in US$

Access premium data and analytics for Novartis AG

6,700+

Clinical Trials

Determine Novartis AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2,100+

Catalyst Calendar

Proactively evaluate Novartis AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

1,800+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novartis AG’s relevant decision makers and contact details.

1,400+

Marketed Drugs

Understand Novartis AG’s commercialized product portfolio to stay one step ahead of the market.

890+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

710+

Pipeline Drugs

Identify which of Novartis AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

180+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

120+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Novartis AG and assess market opportunity for new entrants with patient population 8-year forecasts.

880+

Consumer Market Data Insights

Gain insights from product sales across markets, product categories and channels. Get intelligence on market shares, retail sales footprint, market position and strength for consumer segments and geographies.

490+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

200+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

80+

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

60+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

13+

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Novartis AG (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

7

IT Software Contracts

Improve competitive bidding with insight into all publicly disclosed IT software contracts by IT solutions areas for Novartis AG (including Enterprise applications, IT Security, Information Management, Cloud Computing, IoT and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novartis AG’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Generic Medicines and Biosimilars Cibacen (benazepril hydrochloride)
Pharmaceuticals: Exforge (valsartan and amlodipine besylate)
Cancer Exforge HCT (valsartan, amlodipine besylate and hydrochlorothiazide)
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Financing Agreements In September, the company announced its plans to invest US$300 million in next-generation biotherapeutics.
2022 Official Trials/Tests In September, the company announced tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in phase III trial.
2022 Others In September, the company completion of a Phase II trial in Sjogren’s syndrome.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Novartis AG Johnson & Johnson Pfizer Inc F. Hoffmann-La Roche Ltd AbbVie Inc
Headquarters Switzerland United States of America United States of America Switzerland United States of America
City Basel New Brunswick New York Basel North Chicago
State/Province - New Jersey New York - Illinois
No. of Employees 108,000 141,700 79,000 100,920 50,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Joerg Reinhardt, Ph.D. Chairman Executive Board 2013 66
Vasant Narasimhan, M.D. Chief Executive Officer Senior Management 2018 46
Harry Kirsch Chief Financial Officer Senior Management 2013 57
Karen L. Hale Chief Legal Officer Senior Management 2021 54
Shreeram Aradhye Chief Medical Officer; President - Global Drug Development Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer